drugset / Trial / NCT02919969
Pembrolizumab in Metastatic Anal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
Timeline
- Start
- 2016-10-11
- Primary completion
- 2021-12
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |